Drug therapy in the management of asthma.
In the past decade there has been substantial improvement in the quality of drug therapy for asthma. In part, this reflects the greater sophistication and confidence in the use of bronchodilator drugs, after their role in modifying the intracellular concentration of cyclic nucleotides was discovered. Another advance has come from the appearance of adequate information on theophylline blood levels and half-lives and their variability in man. The increasing availability of theophylline blood levels has aided not only in the selection of therapeutic doses but also in determining the effectiveness of newer products that, for example, promise to have a more sustained effect when given by mouth. The plight of asthmatic patients dependent on oral glucosteroid therapy has been substantially eased with the development of new steroid-sparing drugs that are effective by inhalation.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology; D000242:Cyclic AMP / Q000502:physiology; D006152:Cyclic GMP / Q000502:physiology; D004334:Drug Administration Schedule; D004789:Enzyme Activation / Q000187:drug effects; D005938:Glucocorticoids / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors; D011458:Prostaglandins E / Q000627:therapeutic use; D012138:Respiratory Therapy
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids; D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D011458:Prostaglandins E; D000242:Cyclic AMP; D006152:Cyclic GMP